Odafosfamide

Odafosfamide ((S) -OBI-3424) is a highly selective prodrug bis-alkylating agent activated by aldehyde-keto reductase 1C3 (AKR1C3 () . Odafosfamide is highly cytotoxic to cell lines with high AKR1C3 expression. Odafosfamide exhibits antitumor activity in a variety of tumors with high AKR1C3 expression (such as liver cancer, non-small cell lung cancer, and leukemia) . Odafosfamide can be used in cancer research[1][2].

Product Specifications

CAS Number

[2097713-69-2]

Product Name Alternative

(S) -OBI-3424; (S) -TH-3424; AST-3424

UNSPSC

12352005

Target

17β-HSD

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

95.61

Smiles

C[C@@H](C1=CC(OC2=CC(C(N(C)C)=O)=CC=C2)=C(C=C1)[N+]([O-])=O)OP(N3CC3)(N4CC4)=O

Molecular Formula

C21H25N4O6P

Molecular Weight

460.42

References & Citations

[1]Meng F, et al. A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity. Am J Cancer Res. 2021 Jul 15;11 (7) :3645-3659.|[2]Evans K, et al. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25 (14) :4493-4503.